Contribute Try STAT+ Today

After years of controversy, Teva Pharmaceuticals (TEVA) agreed to pay $925,000 to the state of Mississippi to settle allegations of conspiring to set prices of generic medicines, the first instance in which a state and drug maker have reached a deal over sweeping price-fixing litigation.  Several current and former executives also reached a settlement, according to a court document.

In 2019, Mississippi was one of 43 states that accused more than a dozen generic drug makers and some of their executives of participating in a long-running conspiracy that, ultimately, raised prices for an untold number of Americans. The lawsuit was actually an expanded version of litigation filed in 2016 and the alleged conspiracies were also the focus of a third lawsuit filed last year.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment